Alio Potassium Monitor Cleared for End-Stage Kidney Patients

Alio, a firm focused on wireless remote patient monitoring, has received FDA clearance to add potassium, hematocrit and hemoglobin monitoring to its non-invasive SmartPatch system.

The system consists of a dermal patch, which tracks blood metrics and sends the data to an online portal that alerts clinicians to changes in the patient’s health status.

The latest metrics can benefit patients with end-stage kidney disease (ESKD) as the current standard of care for ESKD is monthly blood draws, whereas the wearable device can take readings every few hours.

With this clearance, the SmartPatch is also approved to monitor skin temperature, lung and other body sounds as well as heart rate.

Broomfield, Colo.-based Alio plans to market the SmartPatch system to hospitals and other healthcare systems.